Who are Ciprofloxacin HCl and Hydrocortisone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): moxifloxacin / dexamethasone, Levofloxacin + dexamethasone followed by dexamethasone, Moxifloxacin / Dexamethasone Ophthalmic Solution, Moxifloxacin and Dexamethasone combined.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ciprofloxacin-hcl-and-hydrocortisone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ciprofloxacin HCl and Hydrocortisone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ciprofloxacin HCl and Hydrocortisone (Ciprofloxacin HCl and Hydrocortisone) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic + corticosteroid combination. Area: Otology / Infectious Disease.

phase 3 Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor Otology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ciprofloxacin HCl and Hydrocortisone (Ciprofloxacin HCl and Hydrocortisone) — Farmoquimica S.A.. Ciprofloxacin kills bacteria by inhibiting DNA gyrase and topoisomerase IV, while hydrocortisone reduces inflammation and immune response in the ear.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ciprofloxacin HCl and Hydrocortisone TARGET	Ciprofloxacin HCl and Hydrocortisone	Farmoquimica S.A.	phase 3	Fluoroquinolone antibiotic + corticosteroid combination	Bacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor
moxifloxacin / dexamethasone	moxifloxacin / dexamethasone	Federal University of São Paulo	marketed	Fluoroquinolone antibiotic + corticosteroid combination	Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor
Levofloxacin + dexamethasone followed by dexamethasone	Levofloxacin + dexamethasone followed by dexamethasone	NTC srl	phase 3	Fluoroquinolone antibiotic + corticosteroid combination	Bacterial DNA gyrase, topoisomerase IV (levofloxacin); glucocorticoid receptor (dexamethasone)
Moxifloxacin / Dexamethasone Ophthalmic Solution	Moxifloxacin / Dexamethasone Ophthalmic Solution	Laboratorios Sophia S.A de C.V.	phase 3	Fluoroquinolone antibiotic + Corticosteroid combination	Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone)
Moxifloxacin and Dexamethasone combined	Moxifloxacin and Dexamethasone combined	Federal University of São Paulo	phase 3	Fluoroquinolone antibiotic + Corticosteroid combination	Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic + corticosteroid combination class)

Farmoquimica S.A. · 1 drug in this class
Federal University of São Paulo · 1 drug in this class
NTC srl · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ciprofloxacin HCl and Hydrocortisone — Competitive Intelligence Brief. https://druglandscape.com/ci/ciprofloxacin-hcl-and-hydrocortisone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab